

## 1H 2015 Sales: + 2% to €8.3 million

- Strong growth momentum in Asia, and notably in China with sales up +124% over the half
- Weaker contribution of indirect sales in the USA during a transition to a more efficient direct sales force
  - Higher growth expected in second half of the year

Aix-en-Provence, July 21, 2015 – SuperSonic Imagine (Euronext: SSI, FR0010526814, PEA-PME eligible), a company specialized in ultrasound medical imaging, today announces its sales for the first half of 2015.

In thousands of euros	2015	2014	Change
Products	2,861	2,612	+10%
Services	371	309	+20%
<b>Q1 sales</b>	<b>3,232</b>	<b>2,921</b>	<b>+11%</b>
Products	4,579	4,788	-4%
Services	440	410	+7%
<b>Q2 sales</b>	<b>5,019</b>	<b>5,198</b>	<b>-3%</b>
Products	7,440	7,400	+1%
Services	811	719	+13%
<b>1H sales</b>	<b>8,251</b>	<b>8,119</b>	<b>+2%</b>
Other revenue*	491	1,097	-55%
<b>Total 1H revenue</b>	<b>8,742</b>	<b>9,216</b>	<b>-5%</b>

*Unaudited data*

NB (\*): this revenue is non-recurrent by nature and is not part of the Group's core business.

Jérôme Destoppeleir, SuperSonic Imagine's Chief Financial Officer, comments: "Asia, and China in particular, where revenue was up +124% over the first half of the year, represents the Group's main growth area. The strong momentum recorded in Asia is continuing thanks to China, which accounted for 28% of our total sales through June 30, 2015 compared to 13% for the same period last year, and to Japan, which has seen a solid performance just months after regulatory approval was granted in that country. Sales in the United States have fallen short of expectations, and have led us to implement a more efficient commercial strategy there by investing more substantially in our direct sales force, which will also enable us to improve further our margins. In Europe, Germany recorded a good first half thanks to the performance of its direct sales network. In France, there has been a market shift compared to last year which impacted Q1 volume negatively. Corrective actions are already showing early positive results. Our differentiated clinical solutions are continuing to gain momentum, especially in the Liver and Breast domains."

In the first half of 2015, SuperSonic Imagine recorded revenue of €8.3 million, an increase of +2% compared with the first half of 2014 (€8.1 million). At constant currency, there would have been a -6% decrease between the 2 periods. Q2 2015 saw a slight fall of -3% in revenue to €5.0 million (compared with 5.2 million and -11% at constant currency), following a Q1 2015 that saw sales increase by +11% to €3.2 million (vs. €2.9 million and +2% at constant currency). This under-

performance was essentially due to the ongoing commercial transition in the United States and the weaker contribution of indirect sales in the distribution mix in this area.

In the first half, SuperSonic Imagine confirmed its strong growth dynamic in Asia, which accounted for 43% of total sales over the first half of the year. Comparatively, the EMEA and Americas zones accounted for 37% and 20% of total sales respectively. Over the first half of 2015, the services revenues grew at 13% and are now 10% of sales against 9% a year ago.

Other revenue comes essentially from access to the Group's technology. This non-recurrent revenue is not written down as sales as it is not part of its core activity.

**Next press release: 1H 2015 results will be published on September 14, 2015**

**About SuperSonic Imagine**

Founded in 2005 and based in Aix-en-Provence (France), SuperSonic Imagine is a company specializing in medical imaging. The company designs, develops and markets a revolutionary ultrasound system, Aixplorer®, with an UltraFast™ platform that can acquire images 200 times faster than conventional ultrasound systems. Aixplorer® is the only system that can image two types of waves: ultrasound waves ensure excellent image quality and shear waves, which allow physicians to visualize and analyze the stiffness of tissue in a real-time, reliable, reproducible and non-invasive manner. This innovation, ShearWave™ Elastography, significantly improves the detection and characterization of numerous pathologies in several applications including breast, thyroid, liver and prostate. SuperSonic Imagine has been granted regulatory clearances for the commercialization of Aixplorer® in the main global markets. Over the past years, SuperSonic Imagine enjoyed the backing of several prestigious investors, among which Auriga Partners, Edmond de Rothschild Investment Partners, Bpifrance, Omnes Capital and NBGI.

For more information about SuperSonic Imagine, please go to [www.supersonicimagine.com](http://www.supersonicimagine.com)

**SuperSonic Imagine**

Marketing & Communication  
Emmanuelle Vella  
[emmanuelle.vella@supersonicimagine.com](mailto:emmanuelle.vella@supersonicimagine.com)  
+33 4 86 79 03 27

**NewCap**

Investor Relations - EU  
Pierre Laurent / Florent Alba  
[supersonicimagine@newcap.fr](mailto:supersonicimagine@newcap.fr)  
+33 1 44 71 98 55

**Blueprint Life Science Group**

Investor Relations - US  
Candice Knoll  
[cknoll@bplifescience.com](mailto:cknoll@bplifescience.com)  
+1 415 375 3340 Ext. 105

**ComCorp**

Media Relations  
Adelaïde Manester  
[amanester@comcorp.fr](mailto:amanester@comcorp.fr)  
+33 1 58 18 32 58 / +33 6 70 45 74 37

